The pain started at 19. Jabbing sensations in the pelvis. Persistent headaches. A constant low-grade malaise that Andy L., a philosophy student at the University of Southampton in England, described in his journal as feeling like two people traveling in different directions. For years, blood tests came back normal. Doctors found nothing wrong. And yet decade after decade, the suffering continued, sending him through nearly 100 medical consultations before a single specialist asked the question that finally changed everything.
His case, reported this week by The Washington Post, is singular in its detail. The systemic failure it describes is not.
Chronic pelvic pain in men is the most commonly diagnosed urological condition in men under 50, and the third most common in men over 50, generating roughly two million clinical visits in the United States every year, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Up to half of all men will experience symptoms associated with the condition at some point in their lives. And yet clinicians, urologists, and researchers continue to describe chronic prostatitis and its related syndromes as persistently misdiagnosed, misclassified, and poorly managed. The gap between how widespread the condition is and how badly medicine handles it is one of the more consequential failures in men’s healthcare.
The mechanism of that failure follows a recognisable pattern. A man presents with pelvic pain, sometimes accompanied by urinary symptoms, painful ejaculation, or low back discomfort. His doctor orders tests. The tests come back negative for bacterial infection. He is then diagnosed with chronic nonbacterial prostatitis, issued a course of antibiotics, and sent away. The antibiotics provide minor, temporary relief because of their analgesic properties, not because they are targeting an infection. The pain returns. The cycle repeats. The National Institutes of Health stated as early as 1995 that the term chronic nonbacterial prostatitis does not adequately explain the symptoms these patients experience. Three decades later, the misdiagnosis loop remains standard care at many clinical entry points.
The more precise clinical term is chronic prostatitis/chronic pelvic pain syndrome, abbreviated CP/CPPS, and it accounts for up to 90 percent of all prostatitis diagnoses. It is not an infection. The exact cause remains unknown. What is known is that the condition frequently overlaps with other chronic pain conditions: irritable bowel syndrome appears in roughly a third of men with widespread pelvic pain, migraine headache in nearly a quarter, fibromyalgia in about 13 percent. The American Urological Association’s 2025 clinical guidelines on male chronic pelvic pain found that 70 percent of men with CP/CPPS also reported pain outside the pelvis, and that those men consistently fared worse across every quality-of-life measure: sleep disturbance, depression, anxiety, and psychological stress all elevated relative to men with localised pain only.
The AUA’s guidelines, the most comprehensive clinical framework for this condition yet published, represent both a belated acknowledgment of how complex CP/CPPS is and an implicit admission of how long the field has lagged. The document notes that the clinical presentation is widely variable, that diagnosis is challenging, and that treatment remains inconsistently effective. For a condition generating two million annual clinical encounters in one country alone, that is a striking statement of institutional candour.
Part of what makes CP/CPPS so persistently elusive is that it shares features with central sensitisation disorders, conditions in which the nervous system becomes pathologically sensitised to pain stimuli in a way that bears no relationship to ongoing tissue damage. This puts it in the same broad category as fibromyalgia and certain headache disorders, conditions where the absence of a visible lesion has historically led clinicians to minimise patient reports or attribute symptoms to psychological causes. For men, this carries a particular stigma: pelvic pain in male patients has been consistently underframed as a serious medical concern relative to the same presentation in women.
What changed for Andy L. was a question from a specialist no previous clinician had thought to ask. The Washington Post, which reported his case this week, does not disclose exactly what was asked, or what diagnosis ultimately emerged. That deliberate opacity is also the story’s most revealing feature: the decisive intervention was not a new drug or a novel technology. It was a question that reorganised the clinical picture. The infrastructure for asking it existed. For decades, no one in nearly 100 consultations used it.
That detail points to a problem the AUA guidelines explicitly identify: the initial assessment for chronic pelvic pain in men requires a comprehensive history, a complete review of systems, and active screening for concurrent psychological stress, anxiety, depression, and major life events. These are listed as clinical principles, not optional extras. The guidelines also recommend screening for neurological, musculoskeletal, and orthopaedic abnormalities. The diagnostic pathway for CP/CPPS is multidisciplinary by design and has been recognised as such in the medical literature for years. The question is why primary care encounters so rarely reflect that complexity before a patient has already spent years in the wrong diagnostic category.
The quality-of-life burden is not abstract. Research comparing CP/CPPS to other chronic conditions has found that the impact on daily functioning is comparable to unstable angina, a recent heart attack, or active Crohn’s disease. Men in the misdiagnosis loop describe the effect on sexual function, intimate relationships, professional life, and mental health in terms that typically accompany far more socially recognised conditions. The condition disproportionately affects younger men in their reproductive years; it is the leading urological diagnosis in men under 50, striking during the years when career and family life are most demanding.
Treatment, when patients finally reach appropriate care, involves pelvic floor physical therapy, multimodal pain management, and in some cases psychological support for the anxiety and depression that long-undiagnosed pain reliably produces. The Pelvic Health and Rehabilitation Center noted in early 2026 that recent studies have begun mapping the neurobiological dimension of CP/CPPS in new ways, particularly around how chronic pelvic pain alters brain function. That research remains at an early stage. It does not yet translate into broadly available clinical protocols.
What the Andy L. case ultimately surfaces is a familiar medical failure pattern: a common condition, a broken first-line diagnostic response, and a patient population spending years generating inconclusive test results while the question that might have unlocked the problem remained unasked. Medicine does not lack the tools to do better with chronic pelvic pain in men. What it has lacked, consistently, is the clinical culture that reaches for those tools before a patient has spent two decades searching for an answer. Whether the AUA’s 2025 guidelines shift that culture at the primary care level, where most of these patients first present and most of the missed diagnoses occur, remains the open question at the centre of this story.
